News | Lift Therapeutics

LIfT’s CEO challenges out dated thinking that therapies focused on T-Cells alone are enough to achieve complete remission in most solid tumours

During a presentation at the Biotech Showcase, our CEO, Alex Blyth challenged the current view that T-cells can do it all, highlighting...

Feb 22, 2024

London, 21st December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a...

Dec 21, 2023

LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy...

Aug 2, 2023

- LIfT announces successful production of first-in-class neutrophil based cell therapy from iPSCs - Use of iPSCs will enable production...

Jul 6, 2023

IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model IMAN is the world’s first...

May 4, 2023

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid

Mar 21, 2023

Stay up-to-date with our progress and latest news.